Intellectual Thoughts by Sanjay Panda: Two indian comapnies in the list of top 10 US generic player


Two indian comapnies in the list of top 10 US generic player

In a first, two Indian drug firms, Lupin Ltd and Dr Reddy’s Ltd, have made it to the list of top 10 generic companies in the fiercely competitive US market, placed eighth and tenth, respectively, in 2009.

These companies have improved their standing in the $34-billion US generic market. Lupin and DRL have also emerged as the fastest growing among the top 10 generic players in the US market, with Lupin growing at 50% and DRL at 40% just when three big players in the top-10 club have shown negative growth. The US generic drugs market is estimated to grow at a CAGR of 8.8% during 2010-2013.

Lupin and DRL’s growth figures also outshine the average growth recorded by the top 10 generic firms at 6.5% in 2009 and the average growth of global pharma industry at just over 5.5%. While Lupin has climbed two notches up to the eighth position by improving its market share from 2.5% in 2008 to over 3.5% in 2009, DRL has broken into the hallowed league year by bettering its market share to 2.7% from 2.1%, according to the National Prescription Audit conducted by IMS in the US.


FE

No comments: